(HUM) Humana (publ) - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0008040653
HUM: Care, Services, Housing, Assistance, Treatment, Support
Humana AB (publ) (ST:HUM) is a leading provider of care services across Scandinavia, operating in Sweden, Finland, Norway, and Denmark. With a market capitalization of 2,057.50M SEK and a P/E ratio of 15.63, the company is well-established in the health care services sector. Founded in 2001 and headquartered in Stockholm, Sweden, Humana has built a diversified portfolio of services across five core segments: Individual & Family, Personal Assistance, Elderly Care, Finland, and Norway.
The company specializes in providing care for individuals with psychosocial disorders, mental illness, and functional impairments. Its offerings include residential care homes, family care services, short-term and special service housing, outpatient care, and specially adapted housing for individuals with disabilities. Additionally, Humana operates elderly care homes, day care services, and adapted housing for the elderly, addressing a wide range of needs across the care continuum.
Humana also focuses on individual and family care for children, young people, and families, as well as housing services for elderly individuals and those with disabilities, mental illness, or substance abuse problems. The company’s comprehensive approach ensures it covers a broad spectrum of care needs, from short-term support to long-term residential care.
From a financial perspective, Humana’s P/B ratio of 0.63 and P/S ratio of 0.20 indicate a valuation that reflects its asset efficiency and revenue generation capabilities. The company’s operations are spread across multiple regions, providing a diversified revenue stream. This geographic and service diversification makes Humana a stable player in the Nordic care services market, with a focus on delivering essential services to vulnerable populations.
For investors and fund managers, Humana’s consistent operational performance and moderate leverage make it a candidate for consideration in health care-focused portfolios. The company’s ability to deliver care services across different demographics and regions positions it as a key player in addressing the growing demand for social and health care services in Scandinavia.
Additional Sources for HUM Stock
HUM Stock Overview
Market Cap in USD | 201m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception |
HUM Stock Ratings
Growth 5y | 1.65% |
Fundamental | 19.2% |
Dividend | 7.50% |
Rel. Strength Industry | 88 |
Analysts | - |
Fair Price Momentum | 51.02 SEK |
Fair Price DCF | 285.80 SEK |
HUM Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 25.0% |
HUM Growth Ratios
Growth Correlation 3m | 69.1% |
Growth Correlation 12m | 87.8% |
Growth Correlation 5y | -68.3% |
CAGR 5y | 2.76% |
CAGR/Max DD 5y | 0.03 |
Sharpe Ratio 12m | -0.13 |
Alpha | 80.12 |
Beta | 0.89 |
Volatility | 36.56% |
Current Volume | 67.8k |
Average Volume 20d | 177.6k |
As of March 15, 2025, the stock is trading at SEK 45.05 with a total of 67,814 shares traded.
Over the past week, the price has changed by -4.66%, over one month by +7.78%, over three months by +23.93% and over the past year by +89.68%.
Neither. Based on ValueRay Fundamental Analyses, Humana (publ) is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 19.23 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HUM as of March 2025 is 51.02. This means that HUM is currently undervalued and has a potential upside of +13.25% (Margin of Safety).
Humana (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, HUM Humana (publ) will be worth about 55.3 in March 2026. The stock is currently trading at 45.05. This means that the stock has a potential upside of +22.75%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 48 | 6.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 55.3 | 22.8% |